

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 December 2022 (01.12.2022)



(10) International Publication Number
WO 2022/250731 A1

- (51) International Patent Classification:
A61K 31/4985 (2006.01) *A61K 9/20* (2006.01)
- (21) International Application Number:
PCT/US2021/061488
- (22) International Filing Date:
01 December 2021 (01.12.2021)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PCT/US2021/034334
26 May 2021 (26.05.2021) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US PCT/US2021/034334 (CIP)
Filed on 26 May 2021 (26.05.2021)
- (71) Applicant: **STRATEGIC DRUG SOLUTIONS, INC.**
[US/US]: 12850 Rock Crest Lane, Chino Hills, California 91709 (US).
- (72) Inventors: **CHOW, Moses**; 12850 Rock Crest Lane, Chino Hills, California 91709 (US). **CHOW, Sheryl L.**; 12850 Rock Crest Lane, Chino Hills, California 91709 (US).
- (74) Agent: **ALTMAN, Daniel, E**; Knobbe, Martens, Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, California 92614 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: FORMULATIONS AND METHODS FOR TREATING ERECTILE DYSFUNCTION




FIG. 7

(57) **Abstract:** The formulation disclosed herein has beneficial properties in enhancing the solubility and permeability (flux) of at least one of vardenafil, sildenafil, and/or related phosphodiesterase inhibitors or other ionizable compounds. In particular, the formulation confers beneficial properties for compounds in crossing the mucosal membrane, leading to an effective plasma drug concentration. In some embodiments, the formulation comprises an organic-aqueous solvent, which may include at least one of an alcohol, a polyether, diethylene glycol monoethyl ether, a medium chain glyceride, one or more saturated polyglycolized C8-C10 glyceride, and/or organic salts, or any combination thereof. In some embodiments, the formulation has a pH of about 3.5 to about 8.0. Also disclosed herein is a use for the formulation in administering one or more compound for the treatment of erectile dysfunction or other diseases, wherein the one or more compound is administered transmucosally (intranasally or sublingually).

[Continued on next page]

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))